Sunday, February 16, 2025
Travel

Travel Guidelines- Stay Updated Stay Safe

Ministry of Civil Aviation (MoCA) review of the COVID-19 International Flight Operations and Arrivals Guidelines – see even reference Due to the spreading nature of COVID-19 and the proliferation of SARS-CoV-2 mutant forms in certain countries, an O.M. was issued on December 30, 2022, with directions for international airline operations and arrivals. The fact that these infections are now spreading in several nations served as the basis for these recommendations. Passengers on all International Flights from/via China, Singapore, Hong Kong, the Republic of Korea, Thailand, and Japan were required to submit a Self-Health Declaration to the Ministry of Civil Aviation’s ‘Air Suvidha’ Portal before boarding their flights.

It has been decided that the current criteria for foreign arrivals need to be amended and updated since these nations have experienced a continuous and large decline in the trajectory of COVID-19 cases over the previous four weeks. The decision was taken when these nations saw the downward trend in trajectory. Here is a rundown of the new and improved rules:

  • Foreign passengers traveling from/via China, Singapore, Hong Kong, the Republic of Korea, Thailand, and Japan are no longer needed to undergo pre-departure COVID-19 testing or file a self-health declaration to the Ministry of Civil Aviation’s ‘Air Suvidha’ website.
  • The present practice of randomly testing 2% of visitors to India (regardless of place of origin) upon arrival in India shall be maintained in order to monitor illnesses caused by mutated strains of SARS-CoV-2 among foreign visitors to India. This will be done so that scientists can monitor the spread of disease.
  • On the thirteenth day of February in the year 2023, at eleven o’clock in the morning, we will begin carrying out the terms of this agreement.
  • The Ministry of Health and Food and Agriculture updated its Guidelines for International Arrivals on February 10, 2023, and a copy of the updated guidelines is included for your reference.
  • The COVID-19 Treatment Guidelines Panel (the Panel) is dedicated to keeping this document up-to-date with the most current knowledge addressing the best treatment of COVID-19 (for a list of Panel members, please see the Panel Roster).
  • Working groups comprised of Panel members create new Guidelines parts and provide suggestions and adjustments to current Guidelines sections. All Guidelines suggestions have been approved by the majority of the Panel (for more information on the development process, see Guidelines Development).

The Guidelines have undergone many significant updates in the previous month, including:

Updates on Tixagevimab and Cilgavimab Use as of March 6, 2023

SARS-CoV-2 Omicron subvariants that are resistant to tixagevimab plus cilgavimab (Evusheld) have reached over 90% prevalence in the United States. This means that in the United States, tixagevimab with cilgavimab cannot be prescribed for the prevention of COVID-19 infection. Tixagevimab and cilgavimab had been proposed as PrEP for COVID-19, however the Panel currently advises against their usage.

Symptoms of SARS-associated coronavirus type 2 Infection

The Panel revised this section to reflect the most recent thinking on newly emerging infections. Extended discussion of COVID-19-related viral or symptom rebound and extended viral shedding with or without symptoms in immunocompromised individuals is included in this section as well.

Nirmatrelvir (Paxlovid) Boosted with Ritonavir

Two case series describing clinical experience with ritonavir-boosted nirmatrelvir in pregnant women with COVID-19 have been included to this section. One case series contained 47 patients, whereas the other included just 7. In each of these case series, the therapy was well tolerated, and neither the mothers nor their newborns had any major ill effects. The Panel maintains its recommendation that pregnant and recently pregnant patients with COVID-19 who are good candidates for ritonavir-boosted nirmatrelvir be administered this treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *